Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization

G E Swaneck, J Fishman, G E Swaneck, J Fishman

Abstract

The interactions of 16 alpha-hydroxyestrone (16 alpha-OHE1), a metabolite of estradiol (E2), with estrogen receptors (ERs) were compared in this study to the classic E2-receptor mechanism in human breast cancer cells MCF-7 in culture. When MCF-7 cells were incubated with radioinert 16 alpha-OHE1 or its 3H-labeled form for 4 weeks, the estrogen bound extensively and irreversibly in a time-dependent fashion to nuclear protein species that correspond to the ER. Here we show that the interactions of 16 alpha-OHE1 with the ER are different from those of E2 with the receptor. Dissociation of tritiated E2-ER or 16 alpha-OHE1-ER complexes, salt extraction, DNase and proteinase K digestion, and ethanol treatment demonstrated that the binding of 16 alpha-OHE1 to the ER corresponds to two different forms: a classical noncovalent interaction similar to that of E2, and a covalent adduct formation between the metabolite and the ER. These complexes localized preferentially in nuclear matrix components as revealed by cell fractionation and probing with a monoclonal anti-ER antibody. [3H]16 alpha-OHE1-ER complexes analyzed by polyacrylamide gel electrophoresis demonstrated a radiolabeled band at approximately 66 kDa that was absent when the exposure of cells was done in the presence of E2 in competition and that was also absent in [3H]E2 incubations. The present results when considered together with our previous findings of elevated activities of estrogen 16 alpha-hydroxylase, the enzyme responsible for the formation of 16 alpha-OHE1, in breast cancer patients and in women at enhanced risk for the disease, suggest that covalent modification of the ER may be one mechanism of malignant transformation in estrogen target tissues.

References

    1. Recent Prog Horm Res. 1969;25:105-60
    1. J Biol Chem. 1951 Nov;193(1):265-75
    1. Annu Rev Biochem. 1976;45:721-46
    1. J Clin Endocrinol Metab. 1980 Sep;51(3):611-5
    1. Anal Biochem. 1980 Mar 1;102(2):344-52
    1. Biochemistry. 1981 Mar 3;20(5):1290-4
    1. Cancer Res. 1982 Jan;42(1):139-44
    1. Proc Natl Acad Sci U S A. 1982 May;79(9):3047-51
    1. Proc Natl Acad Sci U S A. 1982 May;79(10):3320-4
    1. Recent Prog Horm Res. 1982;38:1-40
    1. J Biol Chem. 1983 Mar 25;258(6):3487-95
    1. J Biol Chem. 1984 Apr 25;259(8):4840-5
    1. Eur J Biochem. 1984 May 2;140(3):593-8
    1. J Steroid Biochem. 1984 Apr;20(4B):1077-81
    1. Cancer Res. 1984 Sep;44(9):3724-9
    1. Biochem Biophys Res Commun. 1985 May 16;128(3):1381-7
    1. Science. 1986 Mar 7;231(4742):1150-4
    1. Nature. 1986 Mar 13-19;320(6058):134-9
    1. EMBO J. 1986 May;5(5):891-7
    1. J Steroid Biochem. 1986 Jul;25(1):127-33
    1. J Cell Biol. 1987 Feb;104(2):253-62
    1. Endocr Rev. 1987 Feb;8(1):29-43
    1. Biochemistry. 1987 Apr 21;26(8):2364-73
    1. Nature. 1970 Aug 15;227(5259):680-5

Source: PubMed

3
Abonnere